|
1. Boersma HH, Kietselaer BL, Stolk LM, et al. Past,
present, and future of annexin A5: from protein
discovery to clinical applications. J Nucl Med 2005;
46: 2035-2050.
2. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation
and partial purification of a novel anticoagulant from
arteries of human umbilical cord. Eur J Biochem 1985;
151: 625-629.
3. Gerke V, Moss SE. Annexins: from structure to function.
Physiol Rev 2002; 82: 331-371.
4. Bohn H, Kraus W, [Isolation and characterization of a
new placenta specific protein (PP10) (author's transl)].
Arch Gynecol 1979; 227: 125-134.
5. Tait JF. Clinical application of annexins. In: Seton BA,
ed. Annexin V: molecular structure to cellular function.
R.G. Landes, 1996; 213-220.
6. van Heerde WL, de Groot PG, Reutelingsperger CP. The
complexity of the phospholipid binding protein Annexin
V. Thromb Haemost 1995; 73: 172-179.
7. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic
biological phenomenon with wide-ranging implications in
tissue kinetics. Br J Cancer 1972; 26: 239-257.
8. O'Rourke MG, Ellem KA. John Kerr and apoptosis. Med J
Aust 2000; 173: 616-617.
9. The London Economist. Science and Technology; hornorable
death 1996: 83-84.
10. Darzynkiewicz Z. Apoptosis in antitumor strategies:
modulation of cell cycle or differentiation. J Cell
Biochem 1995; 58: 151-159.
11. Krams SM, Martinez OM. Apoptosis as a mechanism of
tissue injury in liver allograft rejection. Semin Liver
Dis 1998; 18: 153-167.
12. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the
failing human heart. N Engl J Med 1997; 336: 131-141.
13. Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased
surface phosphatidylserine is an early marker of
neuronal apoptosis. J Neurosci Res 1997; 48: 563-570.
14. Thompson CB. Apoptosis in the pathogenesis and
treatment of disease. Science 1995; 267: 1456-1462.
15. http://www.cella.cn/book/15/02.htm.
16. Allen RT, Hunter WJ 3rd, Agrawal DK. Morphological and
biochemical characterization and analysis of apoptosis.
J Pharmacol Toxicol Methods 1997; 37: 215-228.
17. Hengartner MO. The biochemistry of apoptosis. Nature
2000; 404: 770-776.
18. Li X, Darzynkiewicz Z. Labelling DNA strand breaks with
BrdUTP. Detection of apoptosis and cell proliferation.
Cell Prolif 1995;28: 71-79.
19. Casciola-Rosen L, Nicholson DW, Chong T, et al.
Apopain/CPP32 cleaves proteins that are essential for
cellular repair: a fundamental principle of apoptotic
death. J Exp Med 1996; 183: 1957-1964.
20. Blankenberg FG, Katsikis PD, Storrs RW, et al.
Quantitative analysis of apoptotic cell death using
proton nuclear magnetic resonance spectroscopy. Blood
1997; 89: 3778-3786.
21. Cotman CW, Anderson AJ. A potential role for apoptosis
in neurodegeneration and Alzheimer's disease. Mol
Neurobiol 1995;10: 19-45.
22. Zijlstra S, Gunawan J, Burchert W. Synthesis and
evaluation of a 18F-labelled recombinant annexin-V
derivative, for identification and quantification of
apoptotic cells with PET. Appl Radiat Isot 2003; 58:
201-207.
23. Wen X, Wu QP, Ke S, et al. Improved radiolabeling of
PEGylated protein: PEGylated annexin V for noninvasive
imaging of tumor apoptosis. Cancer Biother Radiopharm
2003; 18: 819-827.
24. Glaser M, Collingridge DR, Aboagye EO, et al. Iodine-
124 labelled annexin-V as a potential radiotracer to
study apoptosis using positron emission tomography.
Appl Radiat Isot 2003; 58: 55-62.
25. Ehmann WD, Vance DE. Radiochemistry and nuclear methods
of analysis. 334.
26. Tait JF, Brown DS, Gibson DF, Blankenberg FG, Strauss
HW. Development and characterization of annexin V
mutants with endogenous chelation sites for 99mTc.
Bioconjug Chem 2000; 11: 918-925.
27. Tait JF, Smith C, Blankenberg FG. Structural
requirements for in vivo detection of cell death with
99mTc-annexin V. J Nucl Med 2005; 46: 807-815.
28. Tait JF, Smith C, Gibson DF. Development of annexin V
mutants suitable for labeling with Tc(I)-carbonyl
complex. Bioconjug Chem 2002; 13: 1119-1123.
29. Tait JF, Engelhardt S, Smith C, Fujikawa K.
Prourokinase-annexin V chimeras. Construction,
expression, and characterization of recombinant
proteins. J Biol Chem 1995; 270: 21594-21599.
30. Tanaka K, Einaga K, Tsuchiyama H, Tait JF, Fujikawa K.
Preparation and characterization of a disulfide-linked
bioconjugate of annexin V with the B-chain of
urokinase: an improved fibrinolytic agent
targeted to phospholipid-containing thrombi.
Biochemistry 1996; 35: 922-929.
31. Tait JF, Gibson DF, Smith C. Measurement of the
affinity and cooperativity of annexin V-membrane
binding under conditions of low membrane occupancy.
Anal Biochem 2004; 329: 112-119.
32. Chen HH, Vicente CP, He L, Tollefsen DM, Wun TC. Fusion
proteins comprising annexin V and Kunitz protease
inhibitors are highly potent thrombogenic site-directed
anticoagulants. Blood 2005; 105: 3902-3909.
33. Raynal P, Pollard HB. Annexins: the problem of
assessing the biological role for a gene family of
multifunctional calcium- and phospholipid-binding
proteins. Biochim Biophys Acta 1994; 1197: 63-93.
34. Liao MH, Jan TR, Wey SP, Chiang CC, Chi CW, Fu YK, Shen
LH. A feasible method to prepare 123I-Annexin V for
imaging apoptosis. Ann Nucl Med Sci 2006; 19: 231-238.
|